<div id="readability-page-1"><p>Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Get Free Report) hit a new 52-week high during mid-day trading on Saturday . The stock traded as high as $29.80 and last traded at $28.90, with a volume of 966326 shares trading hands. The stock had previously closed at $24.12.</p><div><p><span></span><span>Get <strong>Eton Pharmaceuticals</strong> alerts:</span></p></div><h2>Analyst Ratings Changes</h2><p>Several equities analysts have issued reports on the stock. HC Wainwright upped their price target on shares of Eton Pharmaceuticals from $37.00 to $52.00 and gave the company a &#34;buy&#34; rating in a research report on Friday, March 20th. Weiss Ratings  reiterated a &#34;sell (d-)&#34; rating on shares of Eton Pharmaceuticals in a research report on Tuesday, April 21st. Zacks Research cut shares of Eton Pharmaceuticals from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Friday, April 17th. B. Riley Financial increased their price objective on shares of Eton Pharmaceuticals from $26.00 to $31.00 and gave the stock a &#34;buy&#34; rating in a research report on Friday, March 20th. Finally, Wall Street Zen upgraded shares of Eton Pharmaceuticals from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Saturday, March 21st. Three equities research analysts have rated the stock with a Buy rating, one  has issued  a Hold rating and one  has given a Sell rating to the company. According to MarketBeat, Eton Pharmaceuticals  has a consensus rating of &#34;Hold&#34; and a consensus target price of $39.33.</p><p><b>View Our Latest Analysis on ETON</b></p><h2>Eton Pharmaceuticals Stock Performance</h2><p>The company has a debt-to-equity ratio of 0.83, a current ratio of 1.57 and a quick ratio of 1.17. The company's 50-day moving average price is $21.94 and its two-hundred day moving average price is $18.48. The company has a market capitalization of $790.70 million, a price-to-earnings ratio of -160.55 and a beta of 0.82. </p><p>Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last posted its quarterly earnings data on Thursday, March 19th. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.07). Eton Pharmaceuticals had a negative return on equity of 2.60% and a negative net margin of 5.75%.The firm had revenue of $21.28 million for the quarter, compared to analyst estimates of $20.58 million.  On average, equities research analysts anticipate that  Eton Pharmaceuticals, Inc. will post 0.82 EPS for the current fiscal year. </p><h2>Institutional Investors Weigh In On Eton Pharmaceuticals</h2><p>Large investors have recently bought and sold shares of the stock. State of Alaska Department of Revenue acquired a new stake in  Eton Pharmaceuticals in the third quarter worth $30,000.  Quarry LP acquired a new stake in  Eton Pharmaceuticals in the third quarter worth $37,000.  Caitong International Asset Management Co. Ltd acquired a new stake in  Eton Pharmaceuticals in the fourth quarter worth $44,000.  Legal &amp; General Group Plc acquired a new stake in  Eton Pharmaceuticals in the second quarter worth $41,000.  Finally, China Universal Asset Management Co. Ltd. acquired a new stake in  Eton Pharmaceuticals in the fourth quarter worth $74,000. 27.86% of the stock is currently owned by institutional investors and hedge funds. </p><h2>About Eton Pharmaceuticals</h2> (Get Free Report)<p>Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.  </p><p>The company's product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.</p><h2>Read More</h2><ul><li>Five stocks we like better than Eton Pharmaceuticals</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Eton Pharmaceuticals Right Now?</h2><p>Before you consider Eton Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eton Pharmaceuticals wasn't on the list.</p><p>While Eton Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ETON

<p>Eton Pharmaceuticals (NASDAQ:ETON) reached a new 12-month high of $29.80, closing at $28.90 with significant trading volume. Analysts have mixed ratings: HC Wainwright raised its price target to $52 (buy), while Weiss Ratings maintained a sell rating. The company reported $21.28 million in revenue but missed EPS estimates. Institutional investors hold 27.86% of shares. Eton focuses on developing pharmaceutical products for rare diseases and has a market cap of $790.70 million.</p>

Eton Pharmaceuticals (NASDAQ:ETON) Reaches New 12-Month High - Time to Buy?